
    
      Patients with non curable solid tumors or lymphoma with anemia (hemoglobin < 10g/dl)
      undergoing palliative care chemotherapy will enter this 12 week single arm open label study.
      Epoetin alfa 40.000-60.000 IU/week will be administered subcutaneously and controlled every 2
      weeks. Up or down titration will be performed according to the currently approved
      prescription guidance for a total of 12 weeks of treatment. Study end points will be assessed
      every 4 weeks until final 12 week visit.
    
  